# Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

> **NCT03847974** · PHASE2 · COMPLETED · sponsor: **LIB Therapeutics LLC** · enrollment: 32 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** LIB003

## Key facts

- **NCT ID:** NCT03847974
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-14
- **Primary completion:** 2020-04-07
- **Final completion:** 2020-08-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03847974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03847974, "Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03847974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*